Latest / The Peptide Effect / The Hidden GLP-1 Switch: How These Drugs May Reprogram Pancreatic Cells

Transcript

The Hidden GLP-1 Switch: How These Drugs May Reprogram Pancreatic Cells · The Peptide Effect

0:00
Welcome back to the Peptide Effect. Before we
0:02
get started, this episode is for educational
0:05
and informational purposes only. It is not medical
0:08
advice, and it is not intended to diagnose, treat,
0:12
cure, or prevent any disease. Nothing discussed
0:16
today should be used as a reason to start, stop,
0:19
increase, decrease, or otherwise change a medication
0:23
or treatment without talking with a qualified
0:25
healthcare professional. Today we're going deep
0:28
into a fascinating new piece of GLP -1 research.
0:32
And when I say deep, I don't mean we're going
0:34
to spend the next half hour drowning in scientific
0:36
terminology. We're going to take what is happening
0:39
at the molecular level, break it down piece by
0:41
piece, and figure out why scientists are paying
0:44
attention to it. Because this research raises
0:46
a really interesting possibility. What if GLP
0:50
-1 receptor agonists aren't simply causing temporary
0:53
metabolic effects while the medication is active?
0:56
What if sustained GLP? One signaling is also
1:00
changing the way insulin producing cells use
1:02
their genetic instructions. That's essentially
1:05
the question behind a 2026 study published in
1:08
the Proceedings of the National Academy of Sciences.
1:11
The researchers identified a mechanism involving
1:14
a protein called Med -14, and a tiny chemical
1:17
modification to that protein appears to play
1:20
an important role in the way pancreatic beta
1:22
cells respond to prolonged GLP, one -receptor
1:26
stimulation. That sentence sounds complicated,
1:29
so we're going to unpack all of it. And the first
1:31
thing we need to understand is what GLP -1 actually
1:35
is. GLP -1 stands for glucagon -like peptide
1:39
-1. GLP - One is a naturally occurring peptide
1:43
hormone produced primarily in the intestine.
1:46
After you eat, specialized intestinal cells release
1:49
GLP. One is part of the body's response to incoming
1:52
nutrients. GLP, one then communicates with receptors
1:56
located in different parts of the body. One particularly
2:00
important location is the pancreas. Inside the
2:03
pancreas are tiny clusters of endocrine cells
2:06
called pancreatic islets. Within those islets
2:09
are several different types of cells. Two of
2:12
the most important for blood sugar regulation
2:14
are alpha cells and beta cells. Alpha cells primarily
2:18
produce glucagon. Beta cells primarily produce
2:21
insulin. Insulin and glucagon work together to
2:24
help maintain glucose balance. When blood glucose
2:27
rises after eating, insulin helps move glucose
2:30
from the bloodstream into cells where it can
2:32
be used for energy or stored for later. When
2:35
blood glucose becomes too low, glucagon helps
2:38
signal the liver to release glucose. It's an
2:41
incredibly sophisticated balancing system. GLP
2:45
-1 participates in that system. When GLP -1 binds
2:49
to receptors on pancreatic beta cells, it enhances
2:52
glucose -dependent insulin secretion. And the
2:56
words glucose -dependent matter. GLP -1 One does
2:59
not simply tell beta cells to release as much
3:02
insulin as possible regardless of what's happening.
3:05
Its insulin stimulating effects are strongly
3:07
influenced by glucose levels. That's one reason
3:10
GLP -1 receptor agonists became so useful in
3:14
the treatment of type 2 diabetes. But GLP -1
3:18
receptor agonists eventually became famous for
3:21
something else. Weight loss. Today most people
3:24
hear GLP 1, and immediately think of medications
3:29
like ozempic and Wegevi. Both contain semaglutide.
3:33
Then there are other medications in the broader
3:35
incretin world, including terzepotide, which
3:38
activates both GLP, 1, and GIP receptors. And
3:43
researchers have continued developing additional
3:45
drugs that target combinations of metabolic receptors.
3:48
But today's study is specifically about GLP,
3:52
1 receptor signaling. And that distinction matters.
3:55
Because we're not talking about everything that
3:58
every incretin -based drug does. We're examining
4:01
one pathway. Now, if you ask the average person
4:04
how a GLP -1 medication works, you'll probably
4:07
hear something like this. It makes you less hungry.
4:10
That's true. But it's incredibly incomplete.
4:14
GLP -1 receptors are involved in a network of
4:17
biological effects. These drugs influence appetite
4:21
and satiety. They affect glucose regulation.
4:24
They influence insulin secretion. They can affect
4:27
gastric emptying. They interact with neural circuits
4:30
involved in food intake. And researchers are
4:34
investigating effects involving the cardiovascular
4:36
system, kidneys, inflammation, the brain, and
4:39
other areas. The more scientists study GLP, one
4:43
biology, the harder it becomes to describe these
4:46
drugs as simply appetite suppressants. And this
4:49
new research gives us another reason why. Researchers
4:52
wanted to understand what sustained GLP -1 receptor
4:56
stimulation actually does inside pancreatic beta
4:58
cells. Not five minutes after the receptor is
5:02
activated. Not simply whether insulin comes out.
5:05
They wanted to look deeper. What happens to gene
5:08
activity? To understand why that's important,
5:10
we need to talk about DNA. Every cell in your
5:13
body contains an enormous library of genetic
5:16
instructions. But cells don't use every instruction
5:20
at the same time. A pancreatic beta cell and
5:23
a skin cell contain essentially the same genome,
5:26
yet they behave completely differently. Why?
5:29
Because they're using different parts of that
5:31
genetic library. Imagine that every cell receives
5:34
an enormous cookbook. The cookbook contains thousands
5:38
and thousands of recipes. A beta cell opens certain
5:42
recipes. A muscle cell opens others. A neuron
5:45
opens another collection. The cookbook may be
5:48
essentially the same, but the instructions being
5:51
read are different. That's gene expression. A
5:54
gene can become more active, less active, or
5:57
relatively quiet depending on what a cell is
5:59
doing. Cells constantly adjust gene expression
6:03
in response to signals. Hormones can influence
6:06
gene expression. Nutrients can influence it.
6:09
Stress can influence it. Exercise can influence
6:12
it. Medications can influence it. And GLP. One
6:17
signaling can influence it. That does not mean
6:19
GLP. One is rewriting your DNA. That distinction
6:23
is extremely important. Changing gene expression
6:26
and changing the underlying genetic code are
6:29
not the same thing. Think about our cookbook
6:32
again. If I tell you to make the lasagna recipe
6:34
instead of the soup recipe, I haven't rewritten
6:37
your cookbook. I've changed which instructions
6:39
you're using. Gene regulation works on a vastly
6:42
more complicated level, but that's a useful way
6:45
of thinking about it. So how does a signal from
6:48
a GLP, one receptor on a cell surface, eventually
6:51
influence genes located inside the nucleus? There
6:55
has to be a communication system. And there is.
6:58
When the GLP, one receptor, becomes activated,
7:02
it initiates signaling inside the cell. One important
7:05
messenger in that process is called cyclic AMP.
7:08
Cyclic AMP then activates an enzyme called protein
7:12
kinase A. Protein kinase A can modify other proteins
7:16
and influence signaling pathways that eventually
7:19
reach the machinery controlling gene transcription.
7:22
One well -known player in this process is called
7:24
CREB. CREB is a transcription factor. A transcription
7:29
factor is essentially a protein involved in controlling
7:32
whether particular genes are expressed. So we
7:35
already had part of the story. GLB, one receptor
7:39
activation leads to intracellular signaling.
7:42
Cyclic A and P increases. Protein kinase A becomes
7:46
involved. CREB becomes involved. Genes respond.
7:51
But scientists wanted to understand how this
7:53
signaling could produce a broader transcriptional
7:55
response, particularly when GLB, one receptor
7:59
stimulation continues for an extended period.
8:02
And that brings us to Med14. Med14 is a protein.
8:06
It is part of something called the mediator complex.
8:10
The mediator complex is a large collection of
8:12
proteins involved in gene transcription. You
8:15
can think of it as part of the bridge connecting
8:17
regulatory signals with the machinery that actually
8:20
reads genes, and Med14 acts as an important structural
8:24
component within that complex. Here's where the
8:27
new discovery comes in. When researchers exposed
8:31
pancreatic beta cells to GLP, one receptor agonist
8:34
signaling, they found that a specific location
8:37
on Med 14 became phosphorylated. That location
8:41
is known as serine 983. If you're thinking, I
8:45
have absolutely no idea what phosphorylation
8:47
means, that's okay. It's much easier to understand
8:50
than it sounds. Phosphorylation is the addition
8:53
of a phosphate group to a molecule, such as a
8:55
protein. Cells use phosphorylation constantly
8:58
as a signaling mechanism. Adding a phosphate
9:01
group can change the behavior of a protein. It
9:05
might change the protein's activity. It might
9:07
change which molecules it interacts with. It
9:10
might change where the protein is located. Or
9:13
it might help turn a biological pathway on or
9:15
off. So when you hear that Med14 becomes phosphorylated
9:19
at serine 983, imagine that a tiny chemical tag
9:23
is being attached at a very specific location
9:26
on this protein. And that tiny modification appears
9:29
to have a surprisingly large effect. That's why
9:33
some people are describing it as a molecular
9:35
switch. It's not literally a light switch. Biology
9:38
is rarely that simple, but it's a useful analogy.
9:42
GLP One receptor stimulation triggers a signaling
9:46
cascade. That signaling eventually reaches Med14.
9:50
Med14 becomes phosphorylated at serine 983. And
9:55
that modification helps the cell activate a much
9:58
broader program of beta -cell -specific genes.
10:01
Now, simply noticing that phosphorylation happens
10:04
would be interesting. But it wouldn't prove that
10:06
the phosphorylation was actually important. Maybe
10:09
it was just something happening in the background.
10:11
Maybe it had nothing to do with the major effects
10:13
researchers were observing. So the scientists
10:16
tested that. They altered Med14 so that this
10:19
particular site could not be phosphorylated normally.
10:22
And then they looked at what happened to the
10:24
cell's response to GLP -1 receptor stimulation.
10:28
This is where things became much more interesting.
10:31
When researchers prevented phosphorylation at
10:33
that Med14 site, much of the normal gene expression
10:37
response to the GLP -1 receptor agonist exendin
10:41
four was disrupted. In other words, when they
10:44
interfered with this tiny molecular switch, a
10:46
much larger portion of the GLP, one response
10:49
stopped working normally. That gives researchers
10:52
evidence that med -14 phosphorylation isn't merely
10:55
happening alongside the response. It appears
10:58
to be an important part of the response. The
11:01
researchers also studied primary pancreatic islets
11:03
from mice carrying the altered med -14 protein.
11:06
Those islets showed impaired regulation of genes
11:09
that normally respond to GLP. One signaling.
11:13
Researchers also observed changes involving the
11:16
balance between pancreatic alpha cells and beta
11:18
cells. That matters because beta cells are the
11:22
cells responsible for insulin production. This
11:24
raises the possibility that this signaling pathway
11:27
plays a role not only in immediate insulin secretion,
11:30
but also in maintaining the broader functional
11:32
state of pancreatic beta cells. And that is where
11:36
this study becomes particularly interesting.
11:38
Because there may be a meaningful difference
11:40
between what GLP -1 signaling does immediately
11:43
and what it does when that signal continues.
11:46
Imagine somebody knocks on your front door. You
11:48
answer the door. That's an immediate response.
11:52
Now imagine that person moves into your house.
11:55
Your entire routine changes. That's a sustained
11:58
response. Obviously cells don't have house guests.
12:02
But the analogy helps explain why duration of
12:05
signaling can matter. Natural GLP. One is released
12:08
after eating and is broken down very quickly
12:11
in the body. It has a very short biological life.
12:15
Pharmaceutical GLP. One receptor agonists were
12:18
engineered to produce much more sustained receptor
12:21
activation. Semiglutide, for example, lasts long
12:26
enough to be administered once weekly. that creates
12:28
a signaling environment that is very different
12:31
from the brief pulse of native GLP, one produced
12:34
after a meal. And scientists want to understand
12:37
the consequences of that difference. This research
12:40
suggests that prolonged GLP, one receptor stimulation
12:44
may allow pancreatic beta cells to move from
12:47
a rapid response into a broader program involving
12:49
gene transcription. In experiments, shorter exposure
12:53
produced more immediate gene responses. With
12:56
sustained exposure, researchers observed activation
12:59
of a broader group of genes associated with beta
13:02
cell function and metabolic adaptation. So instead
13:05
of GLP, one simply knocking on the beta cell's
13:08
door and saying, release some insulin, sustained
13:11
GLP, one signaling may also be telling the cell
13:15
to adjust how it operates. That's a very different
13:17
concept. And it may help us understand why GLP
13:21
One receptor agonists can have biological effects
13:24
that extend beyond their immediate impact on
13:27
insulin secretion. But this is also where we
13:29
need to be extremely careful, because the word
13:32
reprogramming can be misleading. When people
13:35
hear that a drug changes gene expression, some
13:38
immediately interpret that as genetic modification.
13:41
That is not what the study showed. Your DNA contains
13:44
genetic instructions. Gene expression describes
13:47
which of those instructions a cell is using and
13:50
how actively they're being used. Cells change
13:54
gene expression all the time. If you exercise,
13:58
cells change gene expression. If you haven't
14:00
eaten, cells change gene expression. If you eat,
14:04
cells change gene expression. Hormones change
14:07
gene expression. Sleep affects gene expression.
14:11
Stress affects gene expression. The body is constantly
14:15
adapting. So finding that sustained GLP once
14:19
signaling changes transcriptional programs inside
14:21
beta cells does not mean researchers discovered
14:24
that ozenthic permanently alters human DNA. They
14:27
did not. It also doesn't mean these changes necessarily
14:30
remain after someone stops treatment. That's
14:33
an entirely different question. And it's one
14:36
this study did not answer. The word permanent
14:39
is especially important here. This research does
14:42
not establish permanent pancreatic reprogramming.
14:45
It establishes a molecular mechanism through
14:47
which sustained GLP -1 receptor signaling can
14:51
influence gene transcription in experimental
14:53
beta cell systems. That's still a big deal. We
14:57
don't have to exaggerate the finding to make
14:59
it interesting. In fact, I think the actual science
15:02
is more interesting than the exaggerated version,
15:05
because we're seeing how a signal outside a cell
15:07
can eventually influence the machinery controlling
15:10
gene activity inside that cell. Think about the
15:13
chain of events. A GLP, one receptor agonist
15:17
interacts with the receptor. The receptor sends
15:19
a signal into the cell. Cyclic A M P is involved.
15:25
Protein kinase A becomes activated. Proteins
15:28
involved in transcription are modified. Med 14
15:31
becomes phosphorylated at a specific site. The
15:34
mediator complex participates in gene regulation.
15:38
And an entire collection of beta -cell specific
15:41
genes changes its activity. That's incredible.
15:45
One tiny molecular interaction can trigger a
15:47
cascade that eventually affects an entire cellular
15:50
program. And this is one of the reasons peptide
15:53
signaling is so fascinating. Peptides are messengers.
15:57
They don't necessarily need to march into a cell
15:59
and physically perform every job themselves.
16:03
They deliver instructions through receptors.
16:05
The cell then translates those instructions into
16:08
biological action. A peptide binds a receptor,
16:12
and suddenly enzymes activate, signaling molecules
16:14
move, proteins change, genes respond, and cellular
16:19
behavior changes. It's an enormous biological
16:22
conversation happening at a scale we can't see.
16:25
Now, let's talk about something else that is
16:27
likely to get attention from this study. Beta
16:30
cell viability. Researchers found that sustained
16:33
GLP One signaling was associated with transcriptional
16:37
programs supporting beta cell function and viability.
16:40
That sounds incredibly exciting, especially when
16:43
we're talking about diabetes. But we need to
16:45
define what that does and does not mean. It does
16:48
not mean scientists proved that semaglutide regenerates
16:52
the human pancreas. It does not mean ozempic
16:55
grows brand new beta cells in people with diabetes.
16:58
It does not mean GLP. One therapy cures diabetes.
17:02
And it does not mean somebody can take one of
17:04
these medications temporarily and permanently
17:07
restore pancreatic function. What it suggests
17:09
is that GLP, one signaling, can activate gene
17:13
expression programs associated with maintaining
17:15
beta cell function and cellular health. That
17:18
distinction matters. Because supporting the function
17:21
of existing cells is different from creating
17:23
new cells. And findings in experimental models
17:27
do not automatically translate into the same
17:29
outcome in living humans. The study used cultured
17:33
beta -cell models and mouse pancreatic islets.
17:36
The researchers also used exendin -4 as a GLP
17:39
-1 receptor agonist in important parts of the
17:43
experimental work. Exendin -4 is closely connected
17:46
to the development of exonetide, an older GLP
17:49
-1 medication. So we cannot simply replace the
17:52
words exendin -4 with semiglutide and pretend
17:55
the experiment was an ozenthic clinical trial.
17:58
It wasn't. This was mechanistic research. Mechanistic
18:02
research asks how something works. Clinical research
18:06
asks what happens to actual patients. Both are
18:09
incredibly important, but they answer different
18:11
questions. A laboratory experiment can identify
18:14
a pathway and show us exactly what happens when
18:18
researchers interfere with a particular protein.
18:21
A randomized clinical trial can tell us whether
18:23
a treatment improves meaningful outcomes in people.
18:26
Eventually, those different kinds of evidence
18:29
can fit together. But we shouldn't skip steps.
18:32
This study gives us an important piece of the
18:35
mechanism. Now scientists can ask additional
18:37
questions. Does the same Med14 pathway operate
18:41
in human pancreatic beta cells in the same way?
18:44
How strong is the effect in people taking GLP
18:47
-1 receptor agonists? Does semaglutide produce
18:51
the same pattern? How about other GLP -1 receptor
18:55
agonists? Does dose matter? Does duration of
18:58
treatment matter? Do people with type 2 diabetes
19:01
respond differently from people without diabetes?
19:04
Do these transcriptional changes disappear when
19:07
treatment stops? Do some persist? And if they
19:10
persist for how long? Those are the kinds of
19:13
questions that come next. And notice how many
19:15
times I just asked a question instead of giving
19:18
an answer. That's science. One study answers
19:22
something and immediately creates 10 more questions.
19:25
Now, let's talk about semaglutide specifically
19:28
because it's inevitably going to be attached
19:30
to this story. Semaglutide is the active ingredient
19:34
in ozenthic and wegovi. Both activate the GLP
19:37
-1 receptor. So research into GLP -1 receptor
19:41
biology is absolutely relevant to understanding
19:44
how semaglutide works. But this particular study
19:47
does not prove that every molecular effect observed
19:50
with exendin, for occurs identically with semaglutide
19:54
in humans. That's an inference researchers can
19:57
investigate. It's not something we should present
19:59
as established fact. The same caution applies
20:02
even more strongly when we start talking about
20:05
Terzepatide and Rietatrutide. Terzepatide isn't
20:09
simply another GLP -1 receptor agonist. It activates
20:13
both GLP -1 and GIP receptors. Rietatrutide,
20:18
which remains investigational as I'm recording
20:20
this, activates GLP - 1, GP, and glucagon receptors.
20:26
That means those molecules create additional
20:28
signaling beyond GLP1. The Med14 mechanism may
20:33
help explain part of their effects that come
20:35
through the GLP1 receptor, but it cannot automatically
20:39
explain everything those multireceptor drugs
20:42
do. That's why receptor pharmacology matters.
20:45
Two medications can both help someone lose weight
20:48
while producing that outcome through overlapping
20:50
but different biological mechanisms. Now, here's
20:54
another tempting question. Could this research
20:56
explain why some people maintain benefits after
20:59
stopping a GLP -1 medication? Maybe someday we'll
21:03
discover that certain cellular adaptations contribute
21:06
to longer lasting effects. But this study does
21:09
not establish that. And clinically, we know that
21:12
stopping GLP -1 -based obesity treatment frequently
21:15
results in significant weight regain. That tells
21:18
us that whatever cellular adaptations occur,
21:21
they do not simply turn obesity treatment into
21:23
a permanent metabolic reset for everybody. The
21:26
body continues regulating appetite, energy expenditure,
21:30
fat storage, glucose metabolism and body weight
21:33
through an enormous number of interacting pathways.
21:37
There is no single switch that controls all of
21:40
it. Med 14 isn't the weight loss switch. It's
21:43
not the obesity switch. And it's not the diabetes
21:46
switch. It's one component of a transcriptional
21:49
mechanism involved in the beta cell's response
21:51
to GLP, one receptor signaling. That's still
21:55
fascinating. It just isn't magic. And here's
21:59
something else I think people should understand.
22:01
The fact that a medication changes gene expression
22:04
isn't automatically good or bad. Sometimes people
22:08
hear gene expression and immediately become frightened.
22:11
Other people hear it and assume it means some
22:14
incredible regenerative effect. Neither reaction
22:17
is scientifically useful. The important questions
22:20
are which genes change, in which cells, under
22:23
what conditions, for how long, and what those
22:25
changes actually do. That's what researchers
22:28
are trying to figure out. In this case, the changes
22:31
were associated with beta cell -specific programs
22:33
related to cellular function and metabolic adaptation.
22:37
And disrupting Med 14 phosphorylation interfered
22:40
with that response. That gives researchers a
22:43
potential control point to investigate further.
22:46
Could Med 14 eventually become a therapeutic
22:49
target? Possibly, but we're a long way from knowing
22:52
that. Understanding this pathway could potentially
22:55
help researchers design future treatments that
22:57
reproduce desirable parts of GLP, one signaling
23:01
more selectively. Maybe scientists eventually
23:04
identify a downstream target that provides certain
23:07
metabolic benefits without requiring the same
23:09
receptor stimulation. Maybe they find a way to
23:12
better preserve beta cell function. Maybe Med
23:15
14 turns out to be important in predicting treatment
23:18
response. Or maybe additional research shows
23:21
that targeting Med 14 directly isn't practical
23:24
at all. We don't know yet. And that's okay. A
23:27
good scientific discovery doesn't have to immediately
23:30
become a new medication. Sometimes the value
23:33
is simply that another piece of the biological
23:36
puzzle clicks into place. And this particular
23:39
puzzle is huge. Type 2 diabetes isn't simply
23:42
a disease of high blood sugar. It's a complex
23:45
metabolic disease involving insulin resistance,
23:48
beta cell dysfunction, altered hormone signaling,
23:52
changes in liver glucose production, adipose
23:54
tissue biology, and many other factors. When
23:57
insulin resistance develops, pancreatic beta
24:00
cells often compensate by producing more insulin.
24:03
For a while, that compensation may keep blood
24:06
glucose relatively controlled. But beta cells
24:09
can eventually struggle to keep up with the increased
24:11
demand. Beta cell dysfunction is therefore a
24:14
major part of disease progression. Anything that
24:17
helps scientists understand how beta cells maintain
24:19
their identity, function, and viability is potentially
24:23
important. And this study connects GLP, one receptor
24:27
signaling directly to transcriptional machinery
24:30
involved in those processes. That gives us a
24:33
deeper explanation for something scientists have
24:35
observed for years. GLP, one signaling, isn't
24:39
just about what happens immediately after the
24:42
receptor is activated. There are downstream effects,
24:45
and some of those effects reach all the way to
24:48
the level of gene transcription. I also think
24:50
this study gives us a great example of why the
24:53
phrase, we know how this drug works, can be misleading.
24:56
We often know the broad mechanism of a medication
24:59
long before we understand every detail. We knew
25:03
GLP 1 receptor agonists activated GLP 1 receptors.
25:08
We knew they enhanced glucose -dependent insulin
25:11
secretion. We knew they affected appetite and
25:14
gastric emptying. We knew they improved glucose
25:17
control. Then large clinical trials taught us
25:20
more about cardiovascular and kidney outcomes.
25:23
Meanwhile, laboratory researchers kept looking
25:26
deeper into the cellular pathways. And now we're
25:29
discussing phosphorylation of Med 14 at serine
25:32
983. Ten years from now, there will probably
25:36
be another layer. And another one after that.
25:39
Biology doesn't stop becoming complicated just
25:42
because a medication receives approval. In fact,
25:45
widespread clinical use often creates even more
25:48
interest in understanding exactly what a molecule
25:51
is doing. And that's particularly true for GLP
25:55
-1 medications because the clinical effects have
25:57
been so significant. Millions of people are now
26:00
exposed to sustained GLP -1 receptor stimulation.
26:05
That's very different from the brief natural
26:07
GLP -1 signals our bodies evolved to produce
26:10
after meals. Understanding the biological consequences
26:14
of sustained stimulation is therefore incredibly
26:17
important. That includes beneficial effects.
26:20
It also includes potential adverse effects. We
26:23
should study both. Good science isn't supposed
26:26
to prove that GLP -1 medications are amazing.
26:30
And it isn't supposed to prove that they're dangerous.
26:33
It's supposed to determine what they actually
26:35
do. That's why I like the way this particular
26:38
finding should be interpreted. It doesn't need
26:40
a sensational headline. Researchers discovered
26:43
an important molecular mechanism that helps explain
26:46
how sustained GLP, one receptor signaling influences
26:50
gene expression in pancreatic beta cells. That's
26:53
already fascinating. And there is another broader
26:56
lesson here about the way we consume medical
26:58
information online. Social media rewards certainty.
27:03
Science rewards skepticism. Social media wants,
27:06
ozenthic permanently fixes your pancreas. or
27:10
Ozenthic permanently changes your genes. Those
27:13
are dramatic statements. They're also not what
27:16
this study proved. The scientifically responsible
27:18
version contains words like suggests, appears,
27:22
may, and requires further study. Those words
27:25
can sound less exciting, but they are actually
27:28
signs that somebody understands the limits of
27:30
the evidence. Whenever you see a medical headline,
27:33
ask yourself a few questions. Was the research
27:36
done in humans? Was it done in animals? Was it
27:39
done in isolated cells? What drug was actually
27:42
tested? What outcome did researchers actually
27:45
measure? Did they measure weight loss, blood
27:48
sugar, disease progression, gene expression,
27:52
a protein, a receptor? And most importantly,
27:56
does the headline claim more than the experiment
27:58
demonstrated? Those questions can save you from
28:01
an incredible amount of misinformation. In this
28:04
study, researchers weren't giving thousands of
28:06
people semaglutide and then biopsying their pancreases.
28:10
They were investigating molecular mechanisms
28:13
using experimental systems. That's appropriate
28:16
for the question they were asking, but it limits
28:18
the conclusions we can draw about long -term
28:21
human treatment. At the same time, don't make
28:24
the opposite mistake and dismiss the research
28:26
because mice or cultured cells were involved.
28:29
Mechanistic studies are how we discover biological
28:32
pathways. You can't ethically manipulate every
28:35
protein in a living human pancreas just to see
28:37
what happens. Animal models and cellular models
28:41
allow scientists to perform experiments that
28:43
would otherwise be impossible. The key is understanding
28:46
what kind of evidence you're looking at. Mechanistic
28:49
evidence tells us how something may work. Clinical
28:52
evidence tells us whether something meaningfully
28:55
works in patients. When those lines of evidence
28:58
begin supporting each other, our confidence becomes
29:01
much stronger. And that's how medical knowledge
29:04
grows. So, where does this leave us? We have
29:08
a study showing that prolonged GLP -1 receptor
29:11
activation can trigger phosphorylation of Med14
29:14
at a specific site. That modification appears
29:18
to help coordinate a broader transcriptional
29:20
response inside pancreatic beta cells. When researchers
29:24
prevented that modification, much of the expected
29:27
gene response to GLP -1 receptor stimulation
29:30
was disrupted. Mouse pancreatic islets carrying
29:33
the altered Med14 protein also showed impaired
29:36
GLP1, responsive gene regulation and changes
29:40
involving alpha and beta cells. Taken together,
29:44
those findings suggest that Med14 phosphorylation
29:47
is an important part of the molecular machinery
29:49
connecting sustained GLP1 receptor signaling
29:53
to beta cell gene expression. That's the discovery.
29:56
Not permanent pancreatic reprogramming. Not genetic
30:00
modification. Not a cure for diabetes. Not proof
30:04
that GLP -1 medications permanently change your
30:07
metabolism. And definitely not a reason to change
30:10
your medication dose. It's a molecular mechanism.
30:14
But molecular mechanisms matter. Because every
30:17
medication ultimately works through molecular
30:20
mechanisms. The weight on the scale is the final
30:23
visible result of thousands of invisible biological
30:26
events. Appetite is regulated through signaling.
30:29
Insulin secretion is regulated through signaling.
30:33
Glucose metabolism is regulated through signaling.
30:36
And now we're getting a clearer look at how GLP
30:39
-1 signaling communicates with the transcriptional
30:42
machinery inside beta cells. I think that's what
30:44
makes this research so exciting. We're getting
30:47
beyond the question of whether GLP -1 medications
30:51
work. We already have mountains of clinical evidence
30:54
showing that GLP -1 -based therapies can produce
30:58
substantial metabolic effects. Now we're asking
31:01
a more detailed question. What exactly is happening
31:04
inside the cell? And once scientists understand
31:07
that, they can begin asking an even more interesting
31:10
question. Can we use that knowledge to make the
31:13
next generation of treatments better? Maybe future
31:16
metabolic drugs become more targeted. Maybe we
31:19
learn how to preserve beta cell function more
31:22
effectively. Maybe researchers discover combinations
31:24
of pathways that provide stronger benefits with
31:27
fewer side effects. Maybe this mechanism helps
31:30
explain differences between patients. Or maybe
31:34
it simply teaches us something fundamental about
31:37
pancreatic biology. Any of those outcomes would
31:40
make this research worthwhile. And for those
31:42
of us who follow peptide science, I think there's
31:45
something especially beautiful about seeing the
31:48
chain of communication laid out like this. A
31:50
peptide signal begins outside a cell. It touches
31:53
a receptor. The receptor doesn't know anything
31:56
about weight loss. It doesn't know anything about
31:58
ozempic commercials. It doesn't know whether
32:01
somebody wants to lose 20 pounds or control their
32:04
diabetes. It's simply a receptor responding to
32:07
a molecular signal. That signal moves inward.
32:10
One molecule activates another. Enzymes modify
32:13
proteins. Transcription factors respond. The
32:17
mediator complex becomes involved. Med 14 is
32:21
phosphorylated. Genes change their activity.
32:24
And eventually those molecular events contribute
32:26
to changes we can actually measure in a living
32:29
organism. Blood glucose, insulin, appetite, body
32:33
weight, disease risk. That is the part of peptide
32:37
biology I find endlessly fascinating. Something
32:41
microscopic can create an effect large enough
32:44
to change a person's health. And we're still
32:46
figuring out exactly how it happens. So when
32:49
you hear someone say, GLP, one drugs just make
32:52
people stop eating, remember this study. Yes,
32:55
appetite reduction is an important part of their
32:57
effectiveness for weight management. But GLP,
33:01
one biology reaches much further than appetite.
33:04
These receptors participate in complex signaling
33:07
networks throughout the body. And inside pancreatic
33:10
beta cells, sustained GLP, one receptor activation
33:14
appears capable of reaching all the way into
33:16
the machinery controlling gene transcription.
33:19
That doesn't make these drugs magical. It makes
33:22
them biologically complicated. And complicated
33:25
is exactly what we should expect. The human body
33:28
isn't a machine with one button for hunger, another
33:30
for insulin, and another for body weight. It's
33:34
an interconnected network. change one signal,
33:37
and you may affect several pathways downstream.
33:40
Understanding those pathways is how medicine
33:42
moves forward. Five years ago, most people had
33:46
never heard the term GLP -1. Today, people discuss
33:50
GLP -1 medications at dinner tables, gyms, doctor's
33:53
offices, and all over social media. Maybe a few
33:56
years from now, we'll be talking about Med 14
33:58
and wondering how something that sounded so obscure
34:02
became an important part of metabolic medicine.
34:04
Or maybe another discovery will take us in a
34:07
completely different direction. That's the fun
34:10
part. Science isn't finished. And neither is
34:13
our understanding of GLP, one receptor agonist.
34:17
For now, the responsible takeaway is pretty simple.
34:21
Researchers have discovered a molecular mechanism
34:23
that may help explain how sustained GLP, one
34:27
receptor signaling produces broader changes inside
34:29
insulin -producing pancreatic beta cells. A protein
34:33
called Med14 appears to be an important part
34:36
of that mechanism. GLP, one signaling leads to
34:40
phosphorylation of Med14 at serine 983. That
34:44
modification helps support the activation of
34:47
beta cell specific genes. When researchers prevented
34:50
the phosphorylation from occurring normally,
34:53
much of the expected transcriptional response
34:55
was disrupted. That's compelling evidence that
34:58
this little molecular switch matters. But the
35:01
work was largely mechanistic and involved experimental
35:04
beta cell systems and mouse pancreatic islets.
35:07
We still need additional research to understand
35:10
exactly what this means for the human pancreas
35:12
during long -term treatment with medications
35:14
like semaglutide. We don't know whether these
35:17
changes persist after treatment ends. We don't
35:20
know whether this mechanism explains long -term
35:22
clinical outcomes. And we certainly don't have
35:25
evidence that semaglutide permanently reprograms
35:28
the human pancreas. Those questions remain open.
35:32
And open questions aren't a weakness in science.
35:35
They're the reason science keeps moving. Every
35:38
answer creates another question. Every pathway
35:41
we discover reveals another pathway behind it.
35:44
And every time we think we understand a medication
35:47
completely, somebody looks a little deeper and
35:50
finds something we didn't know was there. A few
35:52
years ago, the conversation around GLP -1 medications
35:56
was largely about diabetes. Then weight loss
35:59
dominated the conversation. Now we're talking
36:02
about cardiovascular outcomes, kidney outcomes,
36:05
neurological effects, addiction research, inflammation,
36:08
and molecular changes inside pancreatic beta
36:10
cells. Imagine what we'll be discussing five
36:13
or ten years from now. That's why I think it's
36:16
important to stay curious, without becoming gullible.
36:19
You can be excited about new research and still
36:22
recognize its limitations. You can believe GLP
36:25
-1 medications are incredibly important medical
36:28
tools without pretending they're miracle drugs.
36:30
You can acknowledge their benefits while continuing
36:33
to study their risks. And you can look at a fascinating
36:37
laboratory discovery without immediately turning
36:39
it into a claim about what happens permanently
36:41
inside every person taking ozempic. That's what
36:45
evidence -based curiosity looks like. We don't
36:48
have to choose between excitement and skepticism.
36:51
Good science requires both. And if there is one
36:54
thing I want you to remember from this episode,
36:57
it's this. GLP, one receptor agonists aren't
37:00
simply pressing an appetite button. They're interacting
37:03
with a biological communication system. And this
37:07
study has given us a new glimpse into how far
37:09
that communication can travel. From a receptor
37:12
on the surface of a pancreatic beta cell through
37:15
intracellular signaling to a tiny modification
37:18
on Med14 and ultimately into the machinery controlling
37:21
which genes that cell uses. That's a remarkable
37:25
journey for one signal, and we're only beginning
37:28
to understand where all of those signals eventually
37:30
lead. As always, the peptide effect is for educational
37:34
and informational purposes only. Nothing you've
37:37
heard today is medical advice. And this episode
37:40
should not be used to diagnose or treat a medical
37:43
condition or to make changes to your medications,
37:46
peptides, doses or treatment plan. Always discuss
37:50
those decisions with an appropriately qualified
37:52
healthcare professional. Thanks for listening.
37:54
Keep learning and stay curious.